BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8216813)

  • 1. Enhanced liver MR: contrast agents and imaging strategy.
    Runge VM; Kirsch JE; Wells JW; Awh MH; Bittner DF; Woolfolk CE
    Crit Rev Diagn Imaging; 1993; 34(1-2):1-30. PubMed ID: 8216813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver MRI with contrast enhancement.
    Runge VM
    Crit Rev Diagn Imaging; 1997 Jun; 38(3):207-30. PubMed ID: 9226107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
    Giovagnoni A; Paci E
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
    Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
    Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].
    Zhang HM; Ouyang H; Zhou CW
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):111-5. PubMed ID: 16750014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media].
    Castoldi MC; Fauda V; Scaramuzza D; Vergnaghi D
    Radiol Med; 2000 Sep; 100(3):160-7. PubMed ID: 11148882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterization.
    Kubaska S; Sahani DV; Saini S; Hahn PF; Halpern E
    Clin Radiol; 2001 May; 56(5):410-5. PubMed ID: 11384141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detectability of small liver metastases with gadolinium BOPTA.
    Runge VM; Lee C; Williams NM
    Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU; Reiser MF; Huber AM
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
    Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
    Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
    Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
    Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
    Rofsky NM; Earls JP
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study.
    Hsu JS; Jaw TS; Liu GC; Wang YM; Chen SH; Kuo YT; Jao JC; Li CW; Tsai KB
    J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images.
    Marin D; Iannaccone R; Catalano C; Passariello R
    J Magn Reson Imaging; 2006 Sep; 24(3):690-4. PubMed ID: 16878304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of gadoxetate disodium as a contrast agent for mouse liver imaging: comparison with gadobenate dimeglumine.
    Kiryu S; Inoue Y; Watanabe M; Izawa K; Shimada M; Tojo A; Yoshikawa K; Ohtomo K
    Magn Reson Imaging; 2009 Jan; 27(1):101-7. PubMed ID: 18599243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MultiHance: help or hype?
    Bartolozzi C; Spinazzi A
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S151-9. PubMed ID: 10608411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadobenate dimeglumine (Gd-DTPA) vs gadopentetate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio.
    Pediconi F; Fraioli F; Catalano C; Napoli A; Danti M; Francone M; Venditti F; Nardis P; Passariello R
    Radiol Med; 2003; 106(1-2):87-93. PubMed ID: 12951555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
    Balci NC; Inan N; Anik Y; Erturk MS; Ural D; Demirci A
    Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators.
    Essig M; Tartaro A; Tartaglione T; Pirovano G; Kirchin MA; Spinazzi A
    Acad Radiol; 2006 Jun; 13(6):744-51. PubMed ID: 16679277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.